Acceleron

Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
Endpoints
Acceleron
PAH
FDA
breakthrough therapy
sotatercept
Flag link:
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS
Pharmaceutical Business Review
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
MDS
Flag link:
Go or no go? Covid-19 upstages US regulatory decisions
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Flag link:
Acceleron ditches midstage drug after flop
Acceleron ditches midstage drug after flop
Fierce Biotech
Acceleron
Charcot-Marie-Tooth
clinical trials
ACE-083
Flag link:
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Motley Fool
beta thalassemia
rare disease
drug development
Acceleron
Bristol-Myers Squibb
Bluebird Bio
Sangamo Therapeutics
Vertex Pharmaceuticals
Editas Medicine
Syros Pharmaceuticals
Flag link:
Acceleron’s post-Reblozyl plan comes together
Acceleron’s post-Reblozyl plan comes together
EP Vantage
Acceleron
sotatercept
PAH
JNJ
Bellerophon Therapeutics
United Therapeutics
Vivus
Arena
Novartis
Flag link:
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
Motley Fool
Acceleron
PAH
clinical trials
sotatercept
Flag link:
Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics
Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics
Pharmaceutical Business Review
Acceleron
Fulcrum Therapeutics
R&D
small molecule drugs
pulmonary
Flag link:
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Pharmaceutical Business Review
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
myelodysplastic syndromes
Flag link:
FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease
FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease
BioSpace
Celgene
Acceleron
Reblozyl
anemia
beta thalassemia
Flag link:
Another failed midstage asset for Acceleron, another pipeline test dumped
Another failed midstage asset for Acceleron, another pipeline test dumped
Fierce Biotech
Acceleron
clinical trials
ACE-083
Flag link:
Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension
Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension
Pharmaceutical Business Review
Acceleron
orphan drugs
sotatercept
PAH
Flag link:
In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful
In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful
Fierce Biotech
Celgene
Bristol-Myers Squibb
Acceleron
luspatercept
MDS
beta thalassemia
Flag link:
Celgene and Acceleron Submit BLA for Luspatercept
Celgene and Acceleron Submit BLA for Luspatercept
CP Wire
Celgene
Acceleron
luspatercept
myelodysplastic syndrome
beta thalassemia
Flag link:
Celgene and Acceleron Submit BLA for Luspatercept
Celgene
Acceleron
luspatercept
Flag link:
Acceleron, Stemline price upsized follow-ons
Acceleron, Stemline price upsized follow-ons
BioCentury
Acceleron
Stemline Therapeutics
Celgene
Elzonris tagraxofusp-erzs
Flag link:
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Xconomy
Celgene
M&A
Juno Therapeutics
Kite Therapeutics
Bluebird Bio
Agios Pharmaceuticals
Jounce Therapeutics
BieGene
Acceleron
Flag link:
BMS deal weighs on Celgene partners
BMS deal weighs on Celgene partners
BioCentury
M&A
Celgene
Bristol-Myers Squibb
Acceleron
BeiGene
Flag link:
Top Biotech Stocks to Watch at ASH 2018
Top Biotech Stocks to Watch at ASH 2018
Yahoo/Motley Fool
ASH2018
Celgene
Bluebird Bio
Acceleron
Flag link:
3 Cancer Stocks to Watch in December
3 Cancer Stocks to Watch in December
Motley Fool
Acceleron
luspatercept
Bluebird Bio
bb21217
Amgen
AMG 420
Flag link:

Pages